Plain-English translation of NCT06921928 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new cancer drug called to see if it can help people with advanced stomach, pancreatic, or bile duct cancer. The medication is designed to target cancer cells that have a specific protein on their surface called CLDN18.2. Researchers want to find the right dose, understand how safe the treatment is, and whether it helps shrink tumors.
Advanced stomach and pancreatic cancers are very difficult to treat, and many patients stop responding to standard treatments. This medication represents a new approach that may help patients whose cancers have this specific protein marker, offering hope for those with limited options.
You would receive the medication as the main part of this trial. The study involves two phases: first, researchers test different doses to find the safest level, then they expand to more patients at that dose. You would visit the clinic regularly for blood tests, scans to measure your tumors, and check-ups to monitor how you're tolerating the treatment. Your doctors will closely watch for side effects and measure whether the medication is helping shrink your cancer.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
United States
China